Merestinib is Lilly’s multi-kinase inhibitor tested in Phase II clinical trials for cancers. This talk describes the process research of merestinib, highlighting the route scouting of an advanced indazole intermediate and process analytical technology (PAT) applied on the late-stage chemical transformations for the multi-kilogram synthesis of the active pharmaceutical ingredient (API) using small volume continuous-flow (SVC).